Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Trajectories of Patient-Reported Outcomes after Idecabtagene Vicleucel Vs. Ciltacabtagene Autoleucel CAR T-Cell Therapy Among Patients with Relapsed/Refractory Multiple Myeloma in Standard of Care

Blood (2024) 144 (Supplement 1): 7842.

https://doi.org/10.1182/blood-2024-208668

Published: 2024

Journal Articles

The Differential Effects of Bridging Therapy on Immune Microenvironment and Outcomes with Idecabtagene-Vicleucel in Multiple Myeloma

Praneeth Reddy Sudalagunta, David R. Noyes, Gabriel De Avila, Alexandra Achille, Rafael Renatino-Canevarolo, Xiaohong Zhao, Maria Silva, Angel Perez, Mark B. Meads, Lauren C. Peres, Doris K. Hansen, Kenneth H. Shain, Ariosto Siqueira Silva

Blood (2024) 144 (Supplement 1): 4645.

https://doi.org/10.1182/blood-2024-205631

Published: 2024

Journal Articles

Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 896.

https://doi.org/10.1182/blood-2024-197929

Published: 2024

Journal Articles

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Doris K. Hansen, Lauren C. Peres, Danai Dima, Alicia Richards, Leyla O. Shune, Aimaz Afrough, Shonali Midha, Binod Dhakal, Mehmet H. Kocoglu, Shebli Atrash, Chris Ferreri, Omar Castaneda, James A Davis, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Laura B. Oswald, Gurbakhash Kaur, Oren Pasvolsky, Mahmoud R. Gaballa, Megan M Herr, Peter A. Forsberg, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Hamza Hashmi, Ran Reshef, Douglas W Sborov, Omar Nadeem, Faiz Anwer, Jack Khouri, Shahzad Raza, Djordje Atanackovic, Melissa Alsina, Ciara Louise Freeman, Frederick L. Locke, Peter M. Voorhees, Larry D Anderson, Jr., Shambavi Richard, Thomas Martin, Yi Lin, Krina K. Patel, Surbhi Sidana

Blood (2024) 144 (Supplement 1): 936.

https://doi.org/10.1182/blood-2024-194390

Published: 2024

Journal Articles

Meaningful Change in Patient-Reported Outcomes after CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma in Standard of Care: Differences By Race and Ethnicity

Blood (2024) 144 (Supplement 1): 5165.

https://doi.org/10.1182/blood-2024-208529

Published: 2024

Journal Articles

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 3765.

https://doi.org/10.1182/blood-2024-199609

Published: 2024

Journal Articles

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Lauren C. Peres, Alicia Richards, Surbhi Sidana, Laura B. Oswald, Danai Dima, Aimaz Afrough, Leyla O. Shune, Shonali Midha, Omar Castaneda, Christopher Ferreri, James A Davis, Oren Pasvolsky, Christen M. Dillard, Megan M Herr, Mehmet H. Kocoglu, Shebli Atrash, Brandon Blue, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Mahmoud R. Gaballa, Peter A. Forsberg, Ciara Louise Freeman, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Djordje Atanackovic, Binod Dhakal, Jack Khouri, Shahzad Raza, Ran Reshef, Melissa Alsina, Frederick L. Locke, Omar Nadeem, Faiz Anwer, Larry D Anderson, Jr., Shambavi Richard, Yi Lin, Thomas Martin, Peter M. Voorhees, Krina K. Patel, Doris K. Hansen, Douglas W Sborov

Blood (2024) 144 (Supplement 1): 3785.

https://doi.org/10.1182/blood-2024-210078

Published: 2024

Journal Articles

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Blood blood.2024025945.

https://doi.org/10.1182/blood.2024025945

Published: 2024

Includes: Supplemental data

Journal Articles

A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Blood (2023) 142 (Supplement 1): 1004.

https://doi.org/10.1182/blood-2023-174506

Published: 2023

Journal Articles

Facility-Related Healthcare Resource Utilization (HCRU) for Patients Treated with Idecabtagene Vicleucel (Ide-Cel, bb2121) in a Real-World (RW) Setting: A Single-Center Experience

Blood (2023) 142 (Supplement 1): 5081.

https://doi.org/10.1182/blood-2023-173812

Published: 2023

Journal Articles

Selinexor Disrupts Epigenetic Programing and Modulates Immunogenicity in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3301.

https://doi.org/10.1182/blood-2023-190658

Published: 2023

Journal Articles

Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience

Blood (2022) 140 (Supplement 1): 1856–1858.

https://doi.org/10.1182/blood-2022-164884

Published: 2022

Journal Articles

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

Blood (2022) 140 (Supplement 1): 10427–10429.

https://doi.org/10.1182/blood-2022-163464

Published: 2022

Journal Articles

Baseline Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Blood (2022) 140 (Supplement 1): 12778–12780.

https://doi.org/10.1182/blood-2022-158080

Published: 2022

Journal Articles

Associations between Patient-Reported Outcomes and 90-Day Response to Chimeric Antigen Receptor T-Cell Therapy: A Bayesian Network Analysis

Laura B. Oswald, Yi Luo, Xiaoyin Li, Aasha I. Hoogland, Brian D. Gonzalez, Doris K. Hansen, Michael D. Jain, Frederick L. Locke, Lauren C. Peres, Kedar Kirtane, Issam El Naqa, Heather S.L. Jim

Blood (2022) 140 (Supplement 1): 10913–10915.

https://doi.org/10.1182/blood-2022-169124

Published: 2022

Journal Articles

Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience

Blood (2022) 140 (Supplement 1): 4642–4645.

https://doi.org/10.1182/blood-2022-164828

Published: 2022

Journal Articles

Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience

Blood (2022) 140 (Supplement 1): 10377–10379.

https://doi.org/10.1182/blood-2022-166058

Published: 2022

Journal Articles

Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient's Monitoring after CAR T-Cell Therapy

Omar Alexis Castaneda Puglianini, Lauren C. Peres, Doris K. Hansen, Taiga Nishihori, Ariel F Grajales-Cruz, Brandon J. Blue, Jason Brayer, Ciara L. Freeman, Kenneth H. Shain, Hien D. Liu, Jose Ochoa, Frederick L. Locke, Rachid C. Baz, Melissa Alsina

Blood (2022) 140 (Supplement 1): 7538–7539.

https://doi.org/10.1182/blood-2022-170135

Published: 2022

Journal Articles

Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy

Blood (2022) 140 (Supplement 1): 623–625.

https://doi.org/10.1182/blood-2022-158478

Published: 2022

Journal Articles

Racial and Ethnic Differences in Clonal Hematopoiesis, Tumor Markers, and Clinical Outcomes of Patients with Multiple Myeloma

Nancy Gillis, Lauren C Peres, Christelle M Colin-Leitzinger, Mingxiang Teng, Raghunandan Reddy Alugubelli, Gabriel De Avila, Dongliang Du, Erin M Siegel, Jamie Teer, Oliver Hampton, Melissa Alsina, Jason Brayer, Brandon J. Blue, Ariosto Siqueira Silva, Rachid Baz, Taiga Nishihori, Kenneth H. Shain

Blood (2021) 138 (Supplement 1): 402.

https://doi.org/10.1182/blood-2021-147340

Published: 2021

NARROW

Trajectories of Patient-Reported Outcomes after Idecabtagene Vicleucel Vs. Ciltacabtagene Autoleucel CAR T-Cell Therapy Among Patients with Relapsed/Refractory Multiple Myeloma in Standard of Care

The Differential Effects of Bridging Therapy on Immune Microenvironment and Outcomes with Idecabtagene-Vicleucel in Multiple Myeloma

Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Meaningful Change in Patient-Reported Outcomes after CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma in Standard of Care: Differences By Race and Ethnicity

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Facility-Related Healthcare Resource Utilization (HCRU) for Patients Treated with Idecabtagene Vicleucel (Ide-Cel, bb2121) in a Real-World (RW) Setting: A Single-Center Experience

Selinexor Disrupts Epigenetic Programing and Modulates Immunogenicity in Multiple Myeloma

Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

Baseline Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Associations between Patient-Reported Outcomes and 90-Day Response to Chimeric Antigen Receptor T-Cell Therapy: A Bayesian Network Analysis

Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience

Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience

Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient's Monitoring after CAR T-Cell Therapy

Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy

Racial and Ethnic Differences in Clonal Hematopoiesis, Tumor Markers, and Clinical Outcomes of Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only